세계의 CRISPR 유전자 편집 시장 : 예측 - 제품 유형별, 기술별, 용도별, 최종 사용자별, 지역별 분석(-2032년)

According to Stratistics MRC, the Global CRISPR Gene Editing Market is accounted for $2.30 billion in 2025 and is expected to reach $12.82 billion by 2032 growing at a CAGR of 27.8% during the forecast period. CRISPR gene editing is a cutting-edge biotechnology tool that enables researchers to precisely modify living things' DNA. Drawing inspiration from a bacterial defense mechanism, CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) employs a protein called Cas9 to cut DNA at specific sites under the guidance of an RNA sequence that can be customized. This gives researchers the ability to precisely add, remove, or replace genetic material. Moreover, CRISPR has revolutionized genetic research and has enormous potential in biotechnology, medicine, and agriculture. It presents exciting opportunities for the development of novel treatments, the improvement of crop traits, and the treatment of genetic disorders.

According to the first government-backed clinical application of CRISPR in Europe, NHS England has approved the use of the gene therapy Casgevy for transfusion-dependent beta-thalassemia. The treatment-initially listed at approximately £1.65 million per patient-is being offered through the NHS to up to 460 eligible patients, marking a historic milestone in the clinical adoption of CRISPR-based therapies across Europe.

Market Dynamics:

Driver:

Growing incidence of genetic conditions

The CRISPR gene editing market is being driven largely by the increasing prevalence of genetic diseases like sickle cell anemia, beta-thalassemia, Huntington's disease, and cystic fibrosis worldwide. In contrast to addressing the underlying genetic causes, traditional treatment options for these conditions are frequently scarce, costly, and symptom-focused. CRISPR directly edits faulty genes, potentially providing a remedy. The need for curative therapies is being fueled by the increased early identification of more patients due to increased awareness and improved diagnostic capabilities. Additionally, with regulatory approvals such as the UK NHS's and FDA's approval of Casgevy, CRISPR is progressing from the experimental stage to practical therapeutic use.

Restraint:

Social and ethical issues

The ethical controversy surrounding the use of CRISPR gene editing, especially in germline editing and human embryos, is one of the biggest obstacles to the market. There are serious worries about "designer babies," unforeseen consequences, and the long-term effects on society when the human genome is altered in ways that can be passed on to future generations. Public acceptance is further complicated by religious, cultural, and philosophical beliefs, particularly when editing is suggested for non-therapeutic enhancements like intelligence or appearance. Furthermore, human germline editing is still prohibited or severely restricted by numerous regulatory bodies.

Opportunity:

Growth into untreatable and rare illnesses

CRISPR presents a game-changing chance to treat thousands of uncommon genetic illnesses for which there is currently no cure. CRISPR may be able to fix certain gene mutations that cause diseases like Tay-Sachs, Duchenne muscular dystrophy, and Leber congenital amaurosis at the molecular level. Small patient populations often make traditional drug development for rare diseases financially unfeasible, but CRISPR's accuracy enables targeted, scalable therapeutic approaches. Additionally, orphan drug designations, priority reviews, and grant funding are being used by governments and regulatory bodies to encourage research into rare diseases.

Threat:

Continuous intellectual property (IP) conflicts

The market for CRISPR gene editing is enmeshed in protracted patent disputes between leading organizations, including the University of California, Berkeley, and the Broad Institute. Who has the authority to use and market different parts of the CRISPR-Cas9 technology is a matter of considerable uncertainty as a result of these legal disputes over the fundamental patents. Licenses are necessary for businesses wishing to create CRISPR-based products, and they can be complicated, costly, and jurisdiction-specific. Without a clear definition of freedom to operate, this could discourage startups, impede innovation, or lead to legal action. Additionally, the ambiguous IP landscape hinders cooperation, raises expenses, and deters potential investors.

Covid-19 Impact:

The COVID-19 pandemic affected the market for CRISPR gene editing in two ways: it brought opportunities and challenges. On the one hand, advancements in therapeutic CRISPR applications were momentarily put on hold due to supply chain disruptions, clinical trial delays, and reallocated research funds. Due to lab capacity reductions and lockdowns, numerous gene-editing initiatives unrelated to COVID-19 experienced delays. However, CRISPR-based diagnostics have advanced rapidly as a result of the pandemic, with tools like SHERLOCK and DETECTR being repurposed for the quick and precise detection of SARS-CoV-2. In addition to increasing public awareness and investor confidence, this real-time application demonstrated CRISPR's adaptability beyond genome editing.

The CRISPR/Cas9 segment is expected to be the largest during the forecast period

The CRISPR/Cas9 segment is expected to account for the largest market share during the forecast period because of its ease of use, effectiveness, and affordability, CRISPR/Cas9, the first and most popular CRISPR system, has completely changed genome editing. It enables targeted gene modifications by causing double-strand breaks at particular DNA locations using a guide RNA and the Cas9 enzyme. It is the cornerstone of contemporary gene editing due to its widespread application in scholarly research, pharmaceutical development, and agricultural biotechnology. Moreover, CRISPR/Cas9 is currently being used in a large number of clinical trials to treat infectious diseases, cancer, and genetic disorders, further solidifying its leading position in the global CRISPR market.

The pharmaceutical and biopharmaceutical companies segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the pharmaceutical and biopharmaceutical companies segment is predicted to witness the highest growth rate. Growing investments in the development of gene therapies, the need for personalized medicine, and the quickening of CRISPR-based drug pipelines are the main drivers of this expansion. To create treatments for infectious diseases, rare genetic diseases, and cancer, these businesses are aggressively incorporating CRISPR technologies. Partnerships with biotech companies and CRISPR pioneers have accelerated clinical trials and regulatory approvals. Additionally, pharmaceutical companies are increasing production and commercialization of CRISPR therapies, such as Casgevy, as they receive approval, securing this market's dominance as the fastest-growing gene editing market.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, mainly because of its early adoption of cutting-edge gene-editing technologies, strong biotechnology infrastructure, and generous research funding. With a concentration of important industry players and academic institutions, favorable regulatory support, and extensive clinical trials related to CRISPR, the United States leads the way. While biotech companies actively seek therapeutic development, government organizations such as the NIH make significant investments in genome-editing research. Furthermore, the area also gains from a robust intellectual property framework and a high degree of public-private cooperation.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, propelled by growing government assistance, precision medicine investments, and biotechnology research. With an increasing number of CRISPR-based research projects and clinical studies, nations like China, Japan, South Korea, and India are making rapid strides in genomics. Market expansion is further supported by funding initiatives and regulatory changes meant to promote biotech innovation. Moreover, Asia-Pacific is positioned as a major emerging hub for the adoption of CRISPR technology due to its large population base, rising prevalence of genetic disorders, and growing interest from international pharmaceutical companies in local partnerships.

Key players in the market

Some of the key players in CRISPR Gene Editing Market include Danaher, Thermo Fisher Scientific, Inc., Merck KGaA, Bio-Rad Laboratories Inc, GenScript Inc, Agilent Technologies, Inc., New England Biolabs, Inc., CRISPR Therapeutics AG, OriGene Technologies, Inc., Synthego Corporation, Cellecta, Inc., Rockland Immunochemicals, Inc., Integrated DNA Technologies, Inc., Beam Therapeutics Inc and Locus Biosciences Inc.

Key Developments:

In June 2025, Thermo Fisher Scientific announced that it has been awarded a five-year, $94.5 million contract by the U.S. Department of Defense (DoD) to supply the Navy with a next-generation dosimetry system alongside updated radiation health and database management software. The U.S. Navy operates the world's most technologically advanced naval fleet and is the largest defense user of dosimetry systems globally.

In April 2025, Merck KGaA has struck a deal to buy U.S. biotech company SpringWorks Therapeutics, for an equity value of $3.9 billion to add rare cancer therapies ahead of expected revenue losses linked to expiring patents. The deal came at a price tag about 20% lower than what analysts expected due to lack of other serious bidders and the overall devaluation of the U.S. biotech sector. CEO Belen Garijo said the challenges emerging in the United States were reflected in the final bid price.

In January 2025, Danaher Corporation announced that it has signed a definitive agreement to sell its Pacific Scientific Aerospace business to Meggitt PLC, a global aerospace and defense company. Danaher simultaneously received a binding offer from Meggitt to acquire the Artus business which remains open for 12 months. As required by French law, Danaher must consult with the Artus works council prior to concluding an agreement for the sale of the Artus business.

Product Types Covered:

• CRISPR Kits & Reagent
• CRISPR Services

Technologies Covered:

• CRISPR/Cas9
• Base Editing
• CRISPR/Cpf1 (Cas12a)
• Prime Editing
• Other Technologies

Applications Covered:

• Agricultural
• Biomedical
• Industrial Biotechnology
• Other Applications

End Users Covered:

• Academic Institutes and Research Centres
• Biotechnology Companies
• Contract Research Organizations (CROs)
• Pharmaceutical and Biopharmaceutical Companies
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 Technology Analysis
• 3.8 Application Analysis
• 3.9 End User Analysis
• 3.10 Emerging Markets
• 3.11 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global CRISPR Gene Editing Market, By Product Type

• 5.1 Introduction
• 5.2 CRISPR Kits & Reagent
  • 5.2.1 Kits and Enzymes
  • 5.2.2 Libraries
  • 5.2.3 Design Tools
  • 5.2.4 Antibodies
  • 5.2.5 Other CRISPR Kits & Reagents
• 5.3 CRISPR Services
  • 5.3.1 gRNA Design and Vector Construction
  • 5.3.2 Cell Line Engineering
  • 5.3.3 Screening Services
  • 5.3.4 Other CRISPR Services

6 Global CRISPR Gene Editing Market, By Technology

• 6.1 Introduction
• 6.2 CRISPR/Cas9
• 6.3 Base Editing
• 6.4 CRISPR/Cpf1 (Cas12a)
• 6.5 Prime Editing
• 6.6 Other Technologies

7 Global CRISPR Gene Editing Market, By Application

• 7.1 Introduction
• 7.2 Agricultural
  • 7.2.1 Crop Trait Improvement
  • 7.2.2 Livestock Genome Editing
  • 7.2.3 Pathogen Resistance
• 7.3 Biomedical
  • 7.3.1 Therapeutic Genome Editing
  • 7.3.2 Disease Models
  • 7.3.3 Functional Genomics
  • 7.3.4 Gene Therapy Research
• 7.4 Industrial Biotechnology
  • 7.4.1 Microbial Strain Engineering
  • 7.4.2 Biofuel Production
  • 7.4.3 Enzyme Optimization
• 7.5 Other Applications

8 Global CRISPR Gene Editing Market, By End User

• 8.1 Introduction
• 8.2 Academic Institutes and Research Centres
• 8.3 Biotechnology Companies
• 8.4 Contract Research Organizations (CROs)
• 8.5 Pharmaceutical and Biopharmaceutical Companies
• 8.6 Other End Users

9 Global CRISPR Gene Editing Market, By Geography

• 9.1 Introduction
• 9.2 North America
  • 9.2.1 US
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 Italy
  • 9.3.4 France
  • 9.3.5 Spain
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 New Zealand
  • 9.4.6 South Korea
  • 9.4.7 Rest of Asia Pacific
• 9.5 South America
  • 9.5.1 Argentina
  • 9.5.2 Brazil
  • 9.5.3 Chile
  • 9.5.4 Rest of South America
• 9.6 Middle East & Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 UAE
  • 9.6.3 Qatar
  • 9.6.4 South Africa
  • 9.6.5 Rest of Middle East & Africa

10 Key Developments

• 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 10.2 Acquisitions & Mergers
• 10.3 New Product Launch
• 10.4 Expansions
• 10.5 Other Key Strategies

11 Company Profiling

• 11.1 Danaher
• 11.2 Thermo Fisher Scientific, Inc.
• 11.3 Merck KGaA
• 11.4 Bio-Rad Laboratories Inc
• 11.5 GenScript Inc
• 11.6 Agilent Technologies, Inc.
• 11.7 New England Biolabs, Inc.
• 11.8 CRISPR Therapeutics AG
• 11.9 OriGene Technologies, Inc.
• 11.10 Synthego Corporation
• 11.11 Cellecta, Inc.
• 11.12 Rockland Immunochemicals, Inc.
• 11.13 Integrated DNA Technologies, Inc.
• 11.14 Beam Therapeutics Inc
• 11.15 Locus Biosciences Inc